1. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China
- Author
-
Yuanyuan Kong, Lianhui Zhao, Yameng Sun, Xiaojuan Ou, Hong You, Jialing Zhou, Min Li, Jidong Jia, and Xiaoning Wu
- Subjects
medicine.medical_specialty ,HBsAg ,Antiviral therapy ,medicine.disease_cause ,Beijing ,Chronic hepatitis ,Internal medicine ,Diagnosis ,Internal Medicine ,medicine ,Clinical care ,Hepatitis B virus ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,Obstetrics and Gynecology ,Entecavir ,High uptake ,Psychiatry and Mental health ,Infectious Diseases ,Pediatrics, Perinatology and Child Health ,Geriatrics and Gerontology ,Chronic Hepatitis B ,Public aspects of medicine ,RA1-1270 ,business ,medicine.drug ,Research Paper ,Clinical care cascade - Abstract
Background High uptake of hepatitis B virus (HBV) tests and antiviral therapy are required to improve the clinical outcomes of patients with chronic hepatitis B (CHB) at the population level. In the current study, we used the Basic Medical Care Insurance for Employees (BMCIE) to investigate the changes of clinical care cascade of CHB in Beijing, China. Methods Records for medical service of CHB patients from January 1, 2010 to December 31, 2018 were retrieved from the BMCIE database. The annual and cumulative rates of CHB patients in care, receiving HBV tests and on antiviral therapy were calculated. The trends of annual percentage changes (APCs) were estimated using Joinpoint regression model. Findings Among estimated HBsAg positive employees, the rate of CHB patients in care increased from 4•77% in 2010 to 18•61% in 2018 (APC=17•3, 95%CI: 14•4-20•4). The rate of HBV tests increased from 4•41% in 2010 to 16•39% in 2018. Among the estimated eligible employees for treatment, the rate of antiviral therapy increased from 3•92% in 2010 to 30•88% in 2018. The proportion of hospital visits for HBV≥4 times per year had increased from 47•07% in 2010 to 65•31% in 2018. By 2018, entecavir (65•07%) and tenofovir (12•98%) had become the predominantly prescribed antiviral agents. Interpretation The rates of CHB patients in care, receiving HBV tests and on antiviral therapy substantially increased in Beijing, China. However, more efforts are still needed to increase the uptake of HBV tests and treatment for achieving the goal of HBV elimination by 2030. Funding Beijing Municipal Science and Technology Commission (No.D161100002716003), National Science and Technology Major Special Project for Infectious Diseases (No.Z191100007619037, No.2018ZX10302204), and Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (No. XXX 0104).
- Published
- 2021